Compare Hershey Co (HSY) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Illumina, Inc. — how do they compare? Hershey Co trades at $161.68 (market cap $32.66B), while Illumina, Inc. trades at $268.33 (market cap $39.95B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Hershey Co pays a 3.57% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Illumina, Inc. for 83 Days on average.
| HSY | ILMN | |
|---|---|---|
Market Cap | $32.66B | $39.95B |
Volume | 1,578,237 | 3,169,503 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $293.69 |
52-Week Low | $157.61 | $91.00 |
Typical Hold Time | 135 Days | 83 Days |
Enterprise Value | $37.79B | $41.31B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $160.34, down 0.29% on the day, with the stock showing bearish technical signals despite strong recent earnings beats. The company maintains solid profitability with a 12.24% net margin and 32.81% ROE, though 2025 net income declined to $883 million from prior years. Analyst consensus remains cautious with 65.72% hold ratings, but the $204.62 price target suggests 27.6% upside potential. Recent corporate developments include international leadership changes and ongoing brand investments to drive demand.
HSY presents a mixed investment case with attractive valuation upside but near-term headwinds. The stock's current price near support levels offers entry opportunity for dividend investors, with the recent dividend resumption signaling management confidence. However, commodity cost pressures and competitive threats in the consumer staples space create execution risks. Institutional ownership trends show mixed signals with both new positions and reductions in Q2 2026.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
